 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12» |
- ||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion, Enrollment change: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 27, 2025
P2, N=49, Completed, Sponsor: Compass Therapeutics
Active, not recruiting --> Completed | N=84 --> 49
- ||| CTX-471 / Compass Therap
Trial completion, Monotherapy, Checkpoint inhibition: KEYNOTE-E65: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (clinicaltrials.gov) - Jun 13, 2025
P1, N=100, Completed, Sponsor: Compass Therapeutics
Active, not recruiting --> Completed | N=84 --> 49 Active, not recruiting --> Completed
- CTX-471 / Compass Therap
Enhanced efficacy of CTX-471, a CD137 agonist antibody, in models of immune checkpoint failure via simultaneous blockade of neo-angiogenesis (Section 39; Poster Board No: 12) - Mar 25, 2025 - Abstract #AACR2025AACR_9237;
Tumor growth inhibition was accompanied by pharmacodynamic evidence consistent with decrease of vascular bed density and enhancement of cellular cytotoxic immunity. CTX-471 monotherapy was still efficacious, albeit blunted, in these IO resistant models.
- CTX-8371 / Compass Therap
A phase 1 study of CTX-8371, a bispecific PD-1/PD-L1 antibody, in patients with advanced malignancies (Section 51; Poster Board No: 13) - Mar 25, 2025 - Abstract #AACR2025AACR_5390;
CTX-471 monotherapy was still efficacious, albeit blunted, in these IO resistant models. Abstract is embargoed at this time.
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion date, Trial primary completion date: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 3, 2025
P2, N=84, Active, not recruiting, Sponsor: Compass Therapeutics
Abstract is embargoed at this time. Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
- | Imfinzi (durvalumab) / AstraZeneca, tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment open: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Jan 29, 2025
P1/2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025 Not yet recruiting --> Recruiting
- | tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment change, Trial completion date, Trial termination: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov) - Jan 28, 2025
P1/2, N=41, Terminated, Sponsor: Handok Inc.
Not yet recruiting --> Recruiting N=92 --> 41 | Trial completion date: Jul 2025 --> Jan 2025 | Active, not recruiting --> Terminated; Change of Development Plan
- || CTX-009 / ABL Bio, Compass Therap
PK/PD data, Journal: Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. (Pubmed Central) - Dec 3, 2024
P1/2
In conclusion, the model well described the plasma concentrations of ABL001/CTX-009 in patients with solid tumors. The simulation suggested that weight-based dose and fixed dose can provide equivalent systemic exposure.
- CTX-471 / Compass Therap
Pharmacodynamic and response biomarkers in the monotherapy arm of a phase 1 trial of CTX-471, a novel anti-CD137 agonist antibody (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_526;
P1
NCT03881488. Approval Number: 20190565 Board Name: Western IRB (WIRB) Board Affiliation: Copernicus Group IRB.
- || CTX-471 / Compass Therap
Enrollment closed, Enrollment change, Monotherapy, Checkpoint inhibition: KEYNOTE-E65: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (clinicaltrials.gov) - Aug 15, 2024
P1, N=100, Active, not recruiting, Sponsor: Compass Therapeutics
Approval Number: 20190565 Board Name: Western IRB (WIRB) Board Affiliation: Copernicus Group IRB. Recruiting --> Active, not recruiting | N=157 --> 100
- |||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment closed: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov) - Aug 13, 2024
P2/3, N=150, Active, not recruiting, Sponsor: Compass Therapeutics
Recruiting --> Active, not recruiting | N=157 --> 100 Recruiting --> Active, not recruiting
- | Imfinzi (durvalumab) / AstraZeneca, tovecimig (CTX-009) / ABL Bio, Compass Therap
New P1/2 trial: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Aug 11, 2024
P1/2, N=50, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | CTX-009 / ABL Bio, Compass Therap
Journal, Metastases: COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. (Pubmed Central) - Jun 11, 2024
P2/3
Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer. The primary end point is ORR, and crossover is allowed.Clinical Trial Registration: NCT05506943 (ClinicalTrials.gov).
- CTX-471 / Compass Therap
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies. (Hall A; Poster Bd #: 14) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2939;
P1
CTX-471 monotherapy demonstrates promising monotherapy anti-tumor activity in refractory patients whose tumors have progressed on approved PD-1 or PD-L1 inhibitors. The combination arm with pembrolizumab is ongoing and will be reported at a later date.
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment closed: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 2, 2024
P2, N=84, Active, not recruiting, Sponsor: Compass Therapeutics
The combination arm with pembrolizumab is ongoing and will be reported at a later date. Recruiting --> Active, not recruiting
- ||| CTX-8371 / Compass Therap
Enrollment open, Metastases: CTX-8371-001: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 21, 2024
P1, N=55, Recruiting, Sponsor: Compass Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- CTX-471 / Compass Therap, CTX-009 / ABL Bio, Compass Therap
The combination of DLL4/VEGF-a blockade and immunomodulation can eliminate MHC class I negative tumors in mice (Section 3) - Mar 5, 2024 - Abstract #AACR2024AACR_6901;
This implies that NK cells might be involved in controlling tumor growth in this setting, and that the combined action of CTX-471 and CTX-009 in the tumor stroma enhances NK cell activity. The findings presented here suggest that CTX-009 may provide enhanced clinical benefit when combined with immunomodulatory agents, such as agonistic anti-CD137 antibodies or PD-1/PD-L1 blockers in tumors where immune checkpoint inhibitors have failed.
- | CTX-8371 / Compass Therap
Journal: A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. (Pubmed Central) - Feb 25, 2024
The combination of CTX-8371 and an agonistic anti-CD137 antibody further increased the anti-tumor efficacy with long-lasting curative therapeutic effect. In summary, CTX-8371 is a novel checkpoint inhibitor that might provide greater clinical benefit compared to current anti-PD-1 and PD-L1 antibodies, especially when combined with agents with orthogonal mechanisms of action, such as agonistic anti-CD137 antibodies.
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion date, Trial primary completion date: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=84, Recruiting, Sponsor: Compass Therapeutics
In summary, CTX-8371 is a novel checkpoint inhibitor that might provide greater clinical benefit compared to current anti-PD-1 and PD-L1 antibodies, especially when combined with agents with orthogonal mechanisms of action, such as agonistic anti-CD137 antibodies. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- ||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion date, Trial primary completion date: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov) - Jan 3, 2024
P2/3, N=150, Recruiting, Sponsor: Compass Therapeutics
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2025
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment closed, Phase classification, Trial primary completion date: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov) - Dec 27, 2023
P1/2, N=92, Active, not recruiting, Sponsor: Handok Inc.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2025 Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial primary completion date: Aug 2024 --> Nov 2023
- CTX-009 / ABL Bio, Compass Therap
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002. (Poster Bd # P16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_365;
Systemic chemotherapy usually begins with gemcitabine, platinum agents, and a checkpoint inhibitor followed by 5-FU and oxaliplatin, irinotecan or a taxane...150 patients will be randomized in a 2:1 ratio to receive either CTX-009 plus paclitaxel or paclitaxel alone...Key secondary objectives include overall survival, progression-free survival, and duration of response. Clinical trial information: 251040.
- ||| CTX-8371 / Compass Therap
New P1 trial, Metastases: CTX-8371-001: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 29, 2023
P1, N=55, Not yet recruiting, Sponsor: Compass Therapeutics
- CTX-8371 / Compass Therap
Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_836;
3 Increased avidity is observed for low doses of CTX8371 due to the multimeric bsAb complexes formation. PD1 loss demonstrated in vivo for cynomolgus monkeys1 might be described by the internalization of bsAb-Target complexes only.
- CTX-009 / ABL Bio, Compass Therap
A Study of CTX-009 With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancer () - Apr 21, 2023 - Abstract #CCF2023CCF_170;
- || navicixizumab (OMP-305B83) / OncXerna Therap, CTX-009 / ABL Bio, Compass Therap
great presentation. curious to know how does Navicixizumab compare to CTX-009 anti-DLL4/VEGF bispecific antibody (Twitter) - Apr 1, 2023
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment closed: A Study of ES104 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 15, 2023
P1/2, N=58, Active, not recruiting, Sponsor: Elpiscience (Suzhou) Biopharma, Ltd.
PD1 loss demonstrated in vivo for cynomolgus monkeys1 might be described by the internalization of bsAb-Target complexes only. Recruiting --> Active, not recruiting
- |||| paclitaxel / Generic mfg., CTX-009 / ABL Bio, Compass Therap
Metastases: #CTX-009 Plus #Paclitaxel Produces Responses in Advanced #Biliary Tract #Cancer https://t.co/OggOwTXdpM via @onclive (Twitter) - Jan 26, 2023
- |||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment open, Trial initiation date: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov) - Jan 11, 2023
P2/3, N=150, Recruiting, Sponsor: Compass Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2022 --> Jan 2023
- CTX-009 / ABL Bio, Compass Therap
Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. (On Demand | Level 1, West Hall; Poster Board No. Q3) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_943;
P2
In subsets of patients who have had multigene panel testing done and whose tumors have been identified as having mutations that drive their disease such as defective mismatch repair, HER-2 overexpression, or NTRK fusions specific treatments with respectively PD-1 or PD-L1 inhibitors, traztuzumab or larotrectinib or entrectinib can also be used effectively...The study is currently activating sites with first patient in expected in 2022. Clinical trial information: NCT05513742.
- CTX-009 / ABL Bio, Compass Therap
Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen. (Available On Demand; Poster Board No. P9) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_639;
P2/3
The study is currently activating sites with first patient in expected to be enrolled in 2022. Clinical trial information: NCT05506943.
- CTX-009 / ABL Bio, Compass Therap
CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study. (Available On Demand; Poster Board No. C10) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_430;
P1b/2a
TRAE rate based on mode of action was high, but DLL4/VEGF targeting in BTC has a potential of development. Further investigation of safety and efficacy of this regimen is warranted.
- ||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment open: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 12, 2022
P2, N=84, Recruiting, Sponsor: Compass Therapeutics
Further investigation of safety and efficacy of this regimen is warranted. Not yet recruiting --> Recruiting
- || CTX-471 / Compass Therap
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy, Checkpoint inhibition: KEYNOTE-E65: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (clinicaltrials.gov) - Dec 2, 2022
P1, N=157, Recruiting, Sponsor: Compass Therapeutics
Not yet recruiting --> Recruiting N=96 --> 157 | Trial completion date: Sep 2022 --> Apr 2025 | Trial primary completion date: Jul 2022 --> Feb 2025
- ICT01 / ImCheck Therap, CTX-2026 / Compass Therap
Characterization of antibodies against BTN2A1 for Vδ2+ γδ T cell-based tumor immunotherapy (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_529;
Results We have also established a pre-clinical humanized tumor model using NOD scid gamma (NSG) mice and showed delayed tumor growth in mice that received 4 rounds of human Vδ2 + γδ T cell adoptive cell transfer in combination with clone 20.1 agonist antibody, which will allow further characterization of our anti-BTN2A1 antibodies. Conclusions Taken together, our study has demonstrated the potential to target BTN2A1 and BTN3A1 for Vγ9Vδ2 + T cell-based cancer immunotherapy development.
- |||| tovecimig (CTX-009) / ABL Bio, Compass Therap
New P2 trial: COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 24, 2022
P2, N=84, Not yet recruiting, Sponsor: Compass Therapeutics
- |||||||| tovecimig (CTX-009) / ABL Bio, Compass Therap
New P2/3 trial: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov) - Aug 18, 2022
P2/3, N=120, Not yet recruiting, Sponsor: Compass Therapeutics
- ||| paclitaxel / Generic mfg., CTX-009 / ABL Bio, Compass Therap
Clinical: #CTX009 Shows Preliminary Activity/Safety in #BiliaryTractCancer #CholangioTwitter #cholangiocarcinoma #bileductcancer #CTX009 #paclitaxel #clinicaltrials https://t.co/lp5iT1yqFa via @targetedonc (Twitter) - Aug 8, 2022
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion date, Trial primary completion date: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov) - Jun 30, 2022
P1b/2a, N=92, Recruiting, Sponsor: Handok Inc.
Conclusions Taken together, our study has demonstrated the potential to target BTN2A1 and BTN3A1 for Vγ9Vδ2 + T cell-based cancer immunotherapy development. Trial completion date: Jan 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Aug 2024
- ||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment open: A Study of ES104 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 22, 2022
P1/2, N=58, Recruiting, Sponsor: Elpiscience (Suzhou) Biopharma, Ltd.
Trial completion date: Jan 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Aug 2024 Not yet recruiting --> Recruiting
- CTX-8371 / Compass Therap
Dose range finding study in non-human primates confirms the unique mechanism of action of CTX-8371, a novel bispecific antibody blocking PD-1 and PD-L1 (Section 32) - Mar 9, 2022 - Abstract #AACR2022AACR_5241;
The dual blockade of PD-1 and PD-L1, combined with PD-1 cleavage, may offer superior benefit compared to current checkpoint inhibitor therapies. RO data as well as murine and NHP PK/PD analyses will guide a projected human dose for future development.
- | tovecimig (CTX-009) / ABL Bio, Compass Therap
New P1/2 trial: A Study of ES104 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 22, 2021
P1/2, N=58, Not yet recruiting, Sponsor: Elpiscience (Suzhou) Biopharma, Ltd.
- CTX-009 / ABL Bio, Compass Therap
[VIRTUAL] Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, Bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors () - Sep 30, 2021 - Abstract #AACRNCIEORTC2021AACR_NCI_EORTC_57;
- || CTX-471 / Compass Therap
Trial completion date, Trial primary completion date, Monotherapy, Checkpoint inhibition: KEYNOTE-E65: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (clinicaltrials.gov) - Aug 18, 2021
P1, N=96, Recruiting, Sponsor: Compass Therapeutics
RO data as well as murine and NHP PK/PD analyses will guide a projected human dose for future development. Trial completion date: Jul 2021 --> Sep 2022 | Trial primary completion date: Mar 2021 --> Jul 2022
- ||| tovecimig (CTX-009) / ABL Bio, Compass Therap
Enrollment change, Trial completion date, Trial primary completion date: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov) - Aug 18, 2021
P1b/2a, N=92, Recruiting, Sponsor: Handok Inc.
Trial completion date: Jul 2021 --> Sep 2022 | Trial primary completion date: Mar 2021 --> Jul 2022 N=18 --> 92 | Trial completion date: May 2022 --> Jan 2024 | Trial primary completion date: May 2021 --> Jul 2023
- || tovecimig (CTX-009) / ABL Bio, Compass Therap
Trial completion, Trial completion date, Trial primary completion date: This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 (clinicaltrials.gov) - Jul 7, 2021
P1/2, N=45, Completed, Sponsor: ABL Bio, Inc.
N=18 --> 92 | Trial completion date: May 2022 --> Jan 2024 | Trial primary completion date: May 2021 --> Jul 2023 Recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021 | Trial primary completion date: Dec 2021 --> Mar 2021
- | CTX-471 / Compass Therap
Journal: Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. (Pubmed Central) - Jun 22, 2021
Extremely high doses of CTX-471 were well tolerated, with no signs of hepatic toxicity. Collectively, these data demonstrate that CTX-471 is a unique CD137 agonist that displays an excellent safety profile and an unprecedented level of monotherapy efficacy against very large tumors.
- CTX-8371 / Compass Therap
[VIRTUAL] Bispecific anti-PD-1/PD-L1 antibody CTX-8371 to promote cellular clustering and PD-1 shedding, antitumor activity and tolerability. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4023;
These unique pharmacological properties of CTX-8371 could explain the enhanced T cell responses to tumor antigens and superior efficacy over current monoclonal antibody therapies . With favorable PK/PD and toxicology profiles in mice and cynomolgus monkeys, CTX-8371 warrants further advancement to clinical testing.
- | asciminib (ABL001) / Novartis
Preclinical, Journal: ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. (Pubmed Central) - Mar 30, 2021
P1/2
More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization. Overall, these findings suggest that the combination therapy of ABL001 with paclitaxel or irinotecan would be a better clinical strategy for the treatment of cancer patients.
- ||| TR009 / ABL Bio, TRIGR Therap
M&A: #TRIGRTherapeutics and #ElpiscienceBiopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for #TR009, a Phase 1B Dual #Angiogenic #BispecificAntibody Targeting #DLL4 #VEGF https://t.co/nbZUeZ3HJp (Twitter) - Jan 21, 2021